4-Methylbenzenecarbothioamide, a hydrogen sulfide donor, inhibits tumor necrosis factor-α and CXCL1 production and exhibits activity in models of pain and inflammation

Eur J Pharmacol. 2019 Aug 5:856:172404. doi: 10.1016/j.ejphar.2019.172404. Epub 2019 May 24.

Abstract

The gasotransmitter hydrogen sulfide (H2S) is known to regulate many pathophysiological processes. Preclinical assays have demonstrated that H2S donors exhibit anti-inflammatory and antinociceptive activities, characterized by reduction of inflammatory mediators production, leukocytes recruitment, edema and mechanical allodynia. In the present study, the effects induced by 4-methylbenzenecarbothioamide (4-MBC) in models of pain and inflammation in mice, the mechanisms mediating such effects and the H2S-releasing property of this compound were evaluated. 4-MBC spontaneously released H2S in vitro in the absence of organic thiols. Intraperitoneal (i.p.) administration of 4-MBC (100 or 150 mg/kg) reduced the second phase of the nociceptive response induced by formaldehyde and induced a long lasting inhibitory effect on carrageenan mechanical allodynia. 4-MBC antiallodynic effect was not affected by previous administration of naltrexone or glibenclamide. 4-MBC (50, 100 or 150 mg/kg, i.p.) induced a long lasting inhibitory effect on paw edema induced by carrageenan. The highest dose (150 mg/kg, i.p.) of 4-MBC inhibited tumor necrosis factor-α and CXCL1 production and myeloperoxidase activity induced by carrageenan. Mechanical allodynia and paw edema induced by carrageenan were not inhibited by the 4-MBC oxo analogue (p-toluamide). In summary, 4-MBC, an H2S releasing thiobenzamide, exhibits antinociceptive and anti-inflammatory activities. These activities may be due to reduced cytokine and chemokine production and neutrophil recruitment. The H2S releasing property is likely essential for 4-MBC activity. Our results indicate that 4-MBC may represent a useful pharmacological tool to investigate the biological roles of H2S.

Keywords: 4-Methylbenzenecarbothioamide; CXCL-1; Hydrogen sulfide; Inflammation; Pain; Tumor necrosis factor-α.

MeSH terms

  • Amides / pharmacology*
  • Amides / therapeutic use
  • Animals
  • Benzene Derivatives / chemistry
  • Benzene Derivatives / pharmacology*
  • Benzene Derivatives / therapeutic use
  • Chemokine CXCL1 / biosynthesis*
  • Disease Models, Animal
  • Edema / drug therapy
  • Hydrogen Sulfide / metabolism*
  • Hyperalgesia / drug therapy
  • Inflammation / drug therapy
  • Inflammation / metabolism
  • Male
  • Mice
  • Motor Activity / drug effects
  • Nociception / drug effects
  • Pain / drug therapy*
  • Pain / metabolism*
  • Thioamides / chemistry
  • Thioamides / pharmacology*
  • Thioamides / therapeutic use
  • Tumor Necrosis Factor-alpha / biosynthesis*

Substances

  • 4-methylbenzenecarbothioamide
  • Amides
  • Benzene Derivatives
  • Chemokine CXCL1
  • Thioamides
  • Tumor Necrosis Factor-alpha
  • Hydrogen Sulfide